Transcutaneous Bilirubinometer Market By Device Type (Portable/Handheld Devices, Benchtop/Stationary Systems); By Indication (Neonatal Jaundice/Hyperbilirubinemia, Hepatitis & Liver Dysfunction, Other Indications); By End User (Hospitals & Nursing Homes, Clinics & Outpatient Centers, Research Laboratories, Home Care Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Transcutaneous Bilirubinometer Market and What Is Driving Its Expansion?

The Global Transcutaneous Bilirubinometer Market was valued at USD 62.9 million in 2025 and is projected to reach USD 109.9 million by 2032, expanding at a CAGR of 8.3% during 2026–2032.

 

A transcutaneous bilirubinometer is a non-invasive medical device used to estimate bilirubin levels in newborns by measuring how light is absorbed and reflected through the skin, usually on the forehead or sternum.

 

The addressable clinical base for the Transcutaneous Bilirubinometer Market remains substantial, as neonatal jaundice affects nearly 60% of term newborns and 80% of preterm newborns during the first week of life. The United States recorded 3,628,934 births in 2024, including approximately 377,800 preterm births based on a 10.41% preterm birth rate. Applying reported jaundice prevalence suggests that nearly 2.25 million U.S. newborns may develop jaundice each year, representing about 62% of annual births. This includes approximately 302,000 preterm and 1.95 million term infants, creating a large recurring population requiring bilirubin assessment in which non-invasive transcutaneous measurement can play a central screening role.

 

Overall, the market is moving toward broader routine bilirubin screening, with large annual birth volumes, premature infant monitoring, reduced reliance on invasive blood sampling and expanding neonatal-care capacity supporting sustained device demand through 2032.

 

Which Segments Are Leading and Growing Fastest in the Transcutaneous Bilirubinometer Market?

By Device Type

Leading and Fastest-Growing Subsegment – Portable / Handheld Devices

Portable / handheld devices represent an estimated 58% of the Transcutaneous Bilirubinometer Market, generating approximately USD 36.48 million in 2025, and are projected to expand at a CAGR of about 9.10% during 2026–2032. Their leading position reflects widespread use for non-invasive, rapid neonatal jaundice screening directly at the bedside. Compact design, easy movement between maternity wards and neonatal units, and immediate bilirubin assessment make these devices particularly valuable for routine newborn monitoring and timely clinical intervention.

 

By Indication

Leading and Fastest-Growing Subsegment – Neonatal Jaundice / Hyperbilirubinemia

Neonatal jaundice and hyperbilirubinemia account for an estimated 88% of the Transcutaneous Bilirubinometer Market, representing approximately USD 55.35 million in 2025 revenue, with the segment projected to expand at a CAGR of 8.50% during 2026–2032. Transcutaneous bilirubinometers enable rapid, non-invasive bilirubin assessment in newborns, helping clinicians identify infants requiring confirmatory total serum bilirubin testing. Their routine use also limits repeated heel-stick blood sampling, reducing pain, skin trauma, and unnecessary invasive testing in neonatal care.

 

By End User

Leading Subsegment – Hospitals & Nursing Homes

Hospitals & Nursing Homes account for an estimated 68% of the Transcutaneous Bilirubinometer Market, representing approximately USD 42.77 million in 2025 revenue, and are projected to expand at a CAGR of nearly 8.00% during 2026–2032. TcB devices are routinely used in maternity and neonatal units for pre-discharge jaundice screening, typically within 24–48 hours after birth, enabling rapid bedside assessment without repeated heel-stick blood sampling. Their use also extends to follow-up and step-down care, where objective bilirubin measurements help identify infants requiring confirmatory serum testing or further clinical intervention.

Fastest-Growing Subsegment – Home Care Settings

Home Care Settings accounted for an estimated 6% of the Transcutaneous Bilirubinometer Market, representing approximately USD 3.77 million in revenue in 2025, and are projected to register the fastest end-user CAGR of nearly 10.10% during 2026–2032. In-home use of transcutaneous bilirubinometers enables rapid, non-invasive, and painless monitoring of neonatal bilirubin levels without repeated heel-prick blood sampling, improving the practicality of follow-up jaundice screening for newborns after hospital discharge and supporting timely clinical referral when elevated bilirubin levels are detected.

 

By Geography

Leading Region – North America

North America accounts for an estimated 34% share of the Transcutaneous Bilirubinometer Market, representing approximately USD 21.39 million in revenue in 2025, and is projected to expand at a CAGR of 7.80% during 2026–2032. Transcutaneous bilirubinometers have shifted from a niche screening option to an integral part of routine newborn care across the region. Their wider use in hospitals, maternity centers, and neonatal units supports earlier jaundice assessment, reduces unnecessary blood sampling, and strengthens point-of-care bilirubin monitoring.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific accounted for an estimated 29% share of the Transcutaneous Bilirubinometer Market, representing approximately USD 18.24 million in revenue in 2025, and is projected to register the fastest regional CAGR of about 10.10% during 2026–2032. Wider adoption of non-invasive neonatal jaundice screening across hospitals, maternity centers, and neonatal care units is strengthening the region’s market position, supported by expanding newborn screening programs, improving access to point-of-care diagnostics, and greater clinical emphasis on early bilirubin assessment.

 

Who Are the Established Device Leaders and Emerging Digital Screening Players in the Transcutaneous Bilirubinometer Market?

Konica Minolta, Inc. – Four Decades of Jaundice Screening Meet Smartphone Innovation

Konica Minolta remains one of the most established companies in transcutaneous bilirubin measurement. The company launched what it describes as the world’s first non-invasive jaundice meter in 1980 and currently manufactures the JM-105, giving it more than four decades of product experience in neonatal bilirubin screening. In July 2024, Konica Minolta also began a collaboration with Picterus AS to advance non-invasive newborn jaundice screening technologies, linking its established hardware platform with newer smartphone-based approaches.

The JM-105 is designed for repeated neonatal TcB measurement and converts optical readings from subcutaneous tissue into an estimated bilirubin value expressed in mg/dL. Konica Minolta states that the device can achieve a full recharge in approximately 2 hours and display up to three previous measurements simultaneously, supporting serial monitoring during the first days after birth.

Drägerwerk AG & Co. KGaA – Connecting Bedside Bilirubin Screening With Hospital Care

Dräger is a major commercial and clinical-market participant through the Dräger Jaundice Meter JM-105, which is distributed as part of the company’s neonatal jaundice screening and treatment portfolio. The system can be used in infants from approximately 24 weeks of gestational age, widening its relevance across both term and premature neonatal populations. It also connects with hospital information systems for electronic transfer of screening results.

Its operating specifications are particularly suited to high-throughput maternity and NICU environments. A fully charged JM-105 can perform approximately 250 measurements, while the xenon light source is rated for around 150,000 measurements. The measurement range extends from 0 to 20 mg/dL, and the device weighs approximately 203 grams, supporting repeated bedside use. The reusable probe also removes the requirement for a disposable tip with every test, which can reduce recurring consumable expenditure in hospitals performing large numbers of screenings.

International Biomedical, Ltd. – BiliChek Opens a New Chapter in Neonatal Screening

International Biomedical has become an important participant following the transfer of the BiliChek product family from Philips. Philips officially states that BiliChek has been divested to International Biomedical, while International Biomedical confirmed that it began supplying and supporting the BiliChek System from April 8, 2026. The company brings more than 50 years of experience in neonatal and perinatal care, making BiliChek a strategic addition to its newborn-care portfolio.

The BiliChek platform provides non-invasive point-of-care bilirubin measurement and incorporates disposable calibration tips, patient-data entry, and connectivity functions. Earlier published BiliChek specifications indicate approximately 200 single measurements per full battery charge, use across infants of 27–42 weeks gestational age, a bilirubin measurement range of 0–20 mg/dL, and a reported correlation coefficient of r = 0.90 with serum bilirubin measurements in the referenced validation data.

Other Companies and Their Market Roles

• Picterus AS: Developing the digital side of bilirubin screening through Picterus Jaundice Pro, a smartphone-based Class IIa medical device; the platform has been clinically validated in 5,000+ newborns across 15+ countries, with more than 9,000 verified scans and use by 500+ healthcare professionals.

• Natus Medical: Participates primarily in the broader neonatal jaundice-management ecosystem through the neoBLUE phototherapy systems, neoBLUE Radiometer and related newborn-care products, rather than being a major current transcutaneous bilirubinometer supplier.

• Philips Healthcare: Historically commercialized the BiliChek transcutaneous bilirubin platform and related BiliCal and BilEclipse consumables, but the BiliChek product family has now been transferred to International Biomedical.

• Beijing M&B Electronic Instruments: Competes primarily through lower-cost portable bilirubin screening devices such as the MBJ-series, addressing hospitals and neonatal-care facilities seeking compact point-of-care systems.

• Ningbo David Medical Device Co., Ltd.: Participates in neonatal-care equipment and bilirubin-screening solutions, with a stronger commercial presence in Asian and other price-sensitive hospital markets.

• Xuzhou Kejian Hi-Tech Co., Ltd.: Supplies portable transcutaneous bilirubin measurement equipment, contributing to the expanding base of competitively priced neonatal screening systems in emerging markets.

 

Analyst Commentary: Which Bilirubin Screening Capabilities Will Win the Next Procurement Cycle?

The Transcutaneous Bilirubinometer Market is moving toward faster, more decentralized neonatal screening as hospitals prioritize non-invasive testing, early discharge monitoring, and reduced dependence on repeated blood sampling. The strongest commercial opportunities are emerging around portable handheld systems, connected bilirubin monitoring, community and outpatient newborn screening, and expansion across high-birth-volume regions where neonatal care infrastructure is improving. Vendors that combine clinical accuracy, low operating cost, digital connectivity, and suitability for repeated bedside measurements are positioned to capture a larger share of future procurement.

 

Transcutaneous Bilirubinometer Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 62.9 Million
Revenue Forecast in 2032	USD 109.9 Million
Overall Growth Rate	CAGR of 8.3% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Device Type, By Indication, By End User, By Geography
By Device Type	Portable / Handheld Devices, Benchtop / Stationary Systems
By Indication	Neonatal Jaundice / Hyperbilirubinemia, Hepatitis & Liver Dysfunction, Other Indications
By End User	Hospitals & Nursing Homes, Clinics & Outpatient Centers, Research Laboratories, Home Care Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	High prevalence of neonatal jaundice, large annual newborn and preterm populations, growing adoption of routine bilirubin screening, reduced reliance on repeated invasive blood sampling, expansion of neonatal-care capacity, increasing demand for portable bedside devices, and development of connected bilirubin-monitoring technologies
Customization Option	Available upon request